Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

A class action lawsuit has been filed against GRAIL, Inc. alleging the company provided materially false and misleading statements regarding its NHS Galleri multi-cancer screening trial. The complaint claims GRAIL concealed that the trial was insufficient to demonstrate reduction in Stage III-IV cancers and failed to disclose detailed results. On February 19, 2026, GRAIL announced the trial's primary endpoint was not achieved, causing significant stock price decline. Investors who purchased GRAIL shares between May 13, 2025, and February 19, 2026, have until August 4, 2026, to apply as lead plaintiff.